for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

DexCom, Inc.

DXCM.OQ

Latest Trade

153.87USD

Change

0.90(+0.59%)

Volume

287,140

Today's Range

150.82

 - 

159.14

52 Week Range

105.05

 - 

178.45

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
152.97
Open
155.79
Volume
287,140
3M AVG Volume
18.16
Today's High
159.14
Today's Low
150.82
52 Week High
178.45
52 Week Low
105.05
Shares Out (MIL)
91.19
Market Cap (MIL)
13,948.72
Forward P/E
164.57
Dividend (Yield %)
--

Next Event

Q3 2019 DexCom Inc Earnings Release

Latest Developments

More

Court Rules That The Patents Asserted Against Dexcom Cgm Systems Are Invalid

Dexcom Reports Q2 Results

Dexcom Reports Q1 Non-GAAP Loss Per Share $0.05

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About DexCom, Inc.

Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company's markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient's receiver and an application on the patient's iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).

Industry

Medical Equipment & Supplies

Contact Info

6340 Sequence Dr

+1.858.2000200

http://www.dexcom.com

Executive Leadership

Kevin R. Sayer

Chairman of the Board, President, Chief Executive Officer

Quentin S. Blackford

Chief Financial Officer, Chief Operating Officer, Principal Accounting Officer, Principal Financial Officer

Jake Steven Leach

Executive Vice President, Chief Technology Officer

Donald M. Abbey

Executive Vice President - Quality and Regulatory Affairs

Andrew K. Balo

Executive Vice President - Regulatory Strategy, Clinical Affairs, and Strategic Partnership Development

Key Stats

1.83 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.6K

2017

0.7K

2018

1.0K

2019(E)

1.4K
EPS (USD)

2016

-0.780

2017

-0.580

2018

0.300

2019(E)

0.929
Price To Earnings (TTM)
--
Price To Sales (TTM)
11.42
Price To Book (MRQ)
20.27
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
152.54
LT Debt To Equity (MRQ)
152.46
Return on Investment (TTM)
-13.07
Return on Equity (TTM)
-11.12

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up